Randall A. Oyer, MD, discusses the importance of the ACCC community during the unprecedented coronavirus disease 2019 pandemic.
Randall A. Oyer, MD, medical director at the Ann B. Barshinger Cancer Institute of Penn Medicine Lancaster General in Pennsylvania, and current president of the Association of Community Cancer Centers (ACCC), discusses the importance of the ACCC community during the unprecedented coronavirus disease 2019 (COVID-19) pandemic.
The pandemic crystalized the importance of community, at home, in the professional setting, and the bigger community known as ACCC, says Oyer. When something unknown happens, we look for precedent, but there was none for this scenario. Members leaned on each other for support, however, during these new and challenging times.
Colleagues within the ACCC community who were at the forefront of the pandemic in areas such as Seattle and New York were able to share their experiences with the community to show what they have done, what they have tried, and what they have learned, Oyer says. Whether physicians interact via programs, blogs, written material, or during physical meetings, physicians in the ACCC community are readily available to help each other in times of need, which is what Oyer believes the community is about.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More